[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-associated-with-cerebrovascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-associated-with-cerebrovascular-disease":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100571317",false,"NCT06718686","Rifaximin SSD in Dementia Trial","Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia","RIDE","Inclusion Criteria:\n\n* Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale.\n* Males and Females Age ≥ 65 years\n* Community living with availability of caregiver to accompany participant to study visits and to participate in the study.\n* Able to consent or legal guardian who can consent (with participant assent).\n* Legally authorized representative (LAR) and caregiver for the study is the same individual.\n* Fluency (both participant and caregiver) in written and spoken English to participate in study visits.\n\nExclusion Criteria:\n\n* Dementia not due to AD or VaD\n* Clinically significant agitation or aggression (requiring treatment with antipsychotic medication)\n* Delusions and\u002For hallucinations\n* Severe psychopathology including major depression\n* Unstable, severe, or poorly controlled medical conditions evident from physical examination or clinical history\n* Visual and\u002For hearing disorder that prevents completion of neuropsychologic evaluations.\n* Diarrhea\n* Hypersensitivity to rifaximin, components of rifaximin,\n* and any rifamycin antimicrobial agent\n* Antibiotic use in the prior 6 months\n* Taking medications that interact with Rifaximin. P-glycoprotein (P-gp) inhibitor treatment is permitted as long as the use of P-gp inhibitors is discussed with the investigator.\n* History of alcohol and\u002For drug abuse\n* Participation in another investigational drug trial in the last 30 days","ALL","65 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.",[27,28],"Dementia Alzheimer Type","Dementia Associated With Cerebrovascular Disease",[30,31,32,33,34],"dementia","rifaximin","gut-brain","Alzheimer's","vascular dementia","RECRUITING","2026-04-01",{"date":38,"type":39},"2026-04-03","ACTUAL",{"date":41,"type":39},"2024-12-30",{"date":43,"type":20},"2027-12-30",{"name":45,"class":46},"Jasmohan Bajaj","FED",""]